Skip to main content

Table 3 Significant p-values from univariate survival analysis of immune metagenes

From: Conservation of immune gene signatures in solid tumors and prognostic implications

  

Immune metagenes

 

Cancer type

Clinical characteristics

T/NK 1

T/NK 2

T/NK 3

B/P/T/NK

B/P

B/M/D

M/D/N 1

M/D/N 2

D (LPS)

Breast (DMFS)

All (n=1954)

**

**

**

**

***

***

   
 

P (high) (n=651)

***

***

***

***

***

***

***

***

**

 

HER2-E (n=281)

***

***

***

***

***

**

**

*

**

 

Basal (n=334)

***

***

***

***

***

**

**

  
 

LN- (n=1498)

**

**

**

**

***

***

   
 

ER- (n=401)

***

***

***

***

***

**

   
 

ER+ (n=1343)

  

*

 

**

***

  

* ↓

 

Luminal B (n=399)

 

*

*

 

*

***

 

*

 
 

Luminal A (n=565)

        

* ↓

 

Normal (n=257)

    

*

    
 

40<Age≤50(n=404)

  

*

*

**

**

   
 

Age>50(n=986)

  

*

 

*

*

   

Colon (OAS)

All (n=232)

   

**

     
 

Grade - MD (n=166)

*

  

*

     
 

Age <60(n=79)

*

  

*

     
 

P (low) (n=78)

   

*

     
 

Gender - M (n=122)

*

*

*

**

     
 

Gender - F (n=110)

        

* ↓

 

Stage II (n=72)

 

* ↓

  

* ↓

* ↓

** ↓

** ↓

** ↓

Lung (OAS)

All (n=757)

 

*

**

*

**

    
 

Stage I (n=490)

 

**

**

*

**

    
 

Sub-stage IB (n=313)

*

**

**

*

**

  

*

 
 

Adj. Chemo - No (n=503)

 

*

**

*

*

    
 

Histology - S (n=183)

 

*

*

 

**

    
 

Histology - A (n=574)

  

*

      
 

60≤Age<70(n=273)

 

*

**

  

*

   
 

P (med) (n=253)

  

*

 

*

    
 

Gender - F (n=333)

  

*

      
 

Gender - M (n=424)

    

*

    

TCGA OV (OAS)

All (n=566)

*

*

*

*

     
 

P (med) (n=189)

**

**

**

*

*

*

*

  
 

P (low) (n=188)

     

* ↓

 

* ↓

 
 

Grade 3 (n=477)

**

*

**

*

     
 

Stage III (n=436)

*

 

*

*

     
 

60≤Age<70(n=136)

   

*

     

TCGA GBM (OAS)

All (n=524)

      

* ↓

* ↓

* ↓

 

Age <60(n=273)

      

* ↓

* ↓

** ↓

 

Gender - F (n=205)

* ↓

* ↓

  

* ↓

* ↓

** ↓

** ↓

 
 

P (high) (n=174)

 

* ↓

   

** ↓

** ↓

** ↓

* ↓

TCGA SKCM (OAS)

All (n=456)

***

***

***

***

***

***

***

***

***

 

Stage ≤ II (n=229)

***

***

***

***

***

***

***

***

***

 

Stage > II (n=191)

***

***

**

**

**

***

**

***

***

 

Gender - F (n=175)

***

***

***

**

***

***

***

***

***

 

Gender - M (n=281)

**

**

*

**

*

**

**

**

**

 

P (low) (n=152)

**

**

**

*

**

**

**

***

***

 

P (med) (n=152)

*

*

   

**

*

*

**

 

P (high) (n=152)

**

**

*

**

**

**

**

**

**

 

Age<50(n=136)

**

**

*

*

*

*

  

**

 

50≤Age<70(n=190)

**

**

*

*

**

***

***

***

**

 

Age≥70(n=130)

**

**

*

**

*

**

*

*

**

 

Breslow dv ≤1.5(n=105)

***

**

**

*

*

***

**

***

**

 

Breslow dv >1.5(n=246)

*

   

*

*

 

*

*

 

Primary Tumor (n=102)

        

*

 

Regional Tumor (n=288)

***

***

***

***

***

***

***

***

***

  1. p-value codes: p≤0.001 (***); 0.001<p≤0.01 (**); 0.01<p≤0.05 (*); Poor outcome (↓)
  2. P (low, med, high) = low, intermediate and high proliferation tertiles. Breslow dv (depth value)
  3. Grade - MD = Moderately Differentiated. Histology - S/A = Squamous Cell Carcinoma/Adenocarcinoma
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us